Product Information
SUMATRIPTAN SUCC 25 MG TABLET is a generic product labeled by Bionpharma Inc., priced at $0.2394 per EA under NDC 69452034472. Its NADAC has been published 203 times since Nov 16, 2022.
FDA first approved this application on Aug 10, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Sumatriptan market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/1
Manufacturer
Bionpharma Inc.NDC
69452034472
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA078284FDA Approved
8/10/2009
TE Code
AB
On Market Since
2/18/2022
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN SUCC 25 MG TABLET has been published 203 times since Nov 16, 2022, and over the history we have for it it has declined 62.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2394 per EA |
|---|---|
| All-time high | $0.6302 (Nov 16, 2022) |
| All-time low | $0.2394 (Sep 23, 2026) |
| 52-week high | $0.3363 |
| 52-week low | $0.2394 |
| Median price | $0.3227 |
| Average price | $0.3387 |
| Largest weekly change | +48.8% (Aug 21, 2024) |
| Weeks tracked | 203 |
| Tracking since | Nov 16, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN SUCC 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN SUCC 25 MG TABLET, manufactured by Bionpharma Inc., is $0.2394 per EA (NDC 69452034472), effective Sep 30, 2026.
How has the price of SUMATRIPTAN SUCC 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN SUCC 25 MG TABLET has declined 62.0%. It has been tracked across 203 weekly CMS publications since Nov 16, 2022.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN SUCC 25 MG TABLET?
Since Nov 16, 2022, the NADAC for SUMATRIPTAN SUCC 25 MG TABLET has ranged from a low of $0.2394 (Sep 23, 2026) to a high of $0.6302 (Nov 16, 2022), with a median of $0.3227 per EA.
Are there cheaper alternatives to SUMATRIPTAN SUCC 25 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SUMATRIPTAN SUCC 25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SUMATRIPTAN SUCC 25 MG TABLET?
SUMATRIPTAN SUCC 25 MG TABLET (NDC 69452034472) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.